result not consistent with the null hypothesis should be assumed to be a false positive. A systematic review of the available systematic reviews confirmed in 2002 that higher-quality trials tended to have less positive results, and found no convincing evidence that any homeopathic preparation exerts clinical effects different from placebo. In 2005, The Lancet medical journal published a meta-analysis of 110 placebo-controlled homeopathy trials and 110 matched medical trials based upon the Swiss government's Programme for Evaluating Complementary Medicine, or PEK. The study concluded that its findings were "compatible with the notion that the clinical effects of homeopathy are placebo effects". This was accompanied by an editorial pronouncing "The end of homoeopathy". A 2017 systematic review and meta-analysis found that the most reliable evidence did not support the effectiveness of non-individualized homeopathy. The authors noted that "the quality of the body of evidence is low." Other meta-analyses include homeopathic treatments to reduce cancer therapy side-effects following radiotherapy and chemotherapy, allergic rhinitis, attention-deficit hyperactivity disorder and childhood diarrhoea, adenoid vegetation, asthma, upper respiratory tract infection in children, insomnia, fibromyalgia, psychiatric conditions and Cochrane Library systematic reviews of homeopathic treatments for asthma, dementia, attention-deficit hyperactivity disorder, induction of labour, upper respiratory tract infections in children, and irritable bowel syndrome. Other reviews covered osteoarthritis, migraines, postoperative ecchymosis and edema, delayed-onset muscle soreness, preventing postpartum haemorrhage, or eczema and other dermatological conditions. Some clinical trials have tested individualized homeopathy, and there have been reviews of this, specifically. A 1998 review found 32 trials that met their inclusion criteria, 19 of which were placebo-controlled and provided enough data for meta-analysis. These 19 studies showed a pooled odds ratio of 1.17 to 2.23 in favour of individualized homeopathy over the placebo, but no difference was seen when the analysis was restricted to the methodologically best trials. The authors concluded that "the results of the available randomized trials suggest that individualized homeopathy has an effect over placebo. The evidence, however, is not convincing because of methodological shortcomings and inconsistencies." Jay Shelton, author of a book on homeopathy, has stated that the claim assumes without evidence that classical, individualized homeopathy works better than nonclassical variations. A 2014 systematic review and meta-analysis found that individualized homeopathic remedies may be slightly more effective than placebos, though the authors noted that their findings were based on low- or unclear-quality evidence. The same research team later reported that taking into account model